Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia par Lambert M, Sanchez P, Bergmans P, Gopal S, Mathews M, Wooller A, Pungor K

Accéder au texte intégral

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia par Emsley R, Hargarter L, Bergmans P, Uglešić B, Sengül AC, Petralia A, Khannanova A, Cherubin P, Schreiner A

Accéder au texte intégral

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phas... par Coates, L, Gossec, L, Theander, E, Bergmans, P, Neuhold, M, Karyekar, CS, Shawi, M, Noel, W, Schett, G, McInnes, IB